drugset / Trial / NCT06216444

A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures

NCT06216444

Phase 4 Unknown 240 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in non-intubated diagnostic and therapeutic procedures

Timeline

Start
2024-01
Primary completion
2024-03
Completion
2024-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Remimazolam Small molecule 5 mg
Subject Remimazolam Small molecule 10 mg

Indications

No indication recorded.